Fig. 5From: Efficacy and safety of adding rivaroxaban to the anti-platelet regimen in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trialsTIMI defined major bleeding observed with the addition of rivaroxaban in patients with coronary artery diseaseBack to article page